Mapping Cancer’s Genome

I will be the first to admit – I am not a science geek and sometimes, reviewing new research intimidates the heck out of me. But this – I get.

According to a study published this month in the Journal Nature, Scientists have charted the most complete cancer genomes to date. I’ll let Michael Stratton, the head researcher explain why this is a big deal for the future. “In addition to sequencing more different kinds of cancers, there will be a "profound benefit" of sequencing more cell lines from the same tumor type, said Stratton. By identifying mutations that show up consistently in hundreds of different tumors of the same type, he said, scientists will be able to pinpoint additional driver mutations of specific cancers. These genes may present new drug targets for cancer therapies.

A complete list of the driver mutations in any particular cancer type can then serve as the ultimate diagnostic tool, Stratton added. Looking at a particular tumor in a particular patient and being able to identify which driver mutations it carries "will give us a good indication of which drugs the patient will respond to," he said, "[giving] us a much more refined way of applying cancer therapy to the benefit of patients."

I found this article in one of my favorite daily emails called “The Scientist.” If you don’t suscribe to www.thescientist.com’s daily email you should. It’s an online magazine about life sciences and their coverage of cancer is pretty consistent, and (good for me) easy to understand.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap